GGrantIndex
← Search

Host-Tumor Interactions Research Program (HT) (Project-002)

$4,735P30FY2018CANIH

Vanderbilt University Medical Center, Nashville TN

Investigators

Linked publications, trials & patents

Trial NCT07016399Trial NCT06593106Trial NCT05501665Trial NCT05361720Trial NCT04765072Trial NCT02702310Trial NCT02685631Trial NCT02677883Trial NCT02676752Trial NCT02672475Trial NCT02658487Trial NCT02600533Trial NCT02489422Trial NCT02480114Trial NCT02457910Trial NCT02448225Trial NCT02440737Trial NCT02374931Trial NCT02359851Trial NCT02324881Trial NCT02296112Trial NCT02269111Trial NCT02240381Trial NCT02236546Trial NCT02170272Trial NCT02151539Trial NCT02148406Trial NCT01996527Trial NCT01928160Trial NCT01901367Trial NCT01660971Trial NCT01230515Trial NCT01198535Trial NCT01141218Trial NCT01098669Trial NCT01098643Trial NCT01096407Trial NCT01096394Trial NCT01096381Trial NCT01077440Trial NCT01031446Trial NCT01013506Trial NCT01009931Trial NCT01007422Trial NCT00993694Trial NCT00993135Trial NCT00987766Trial NCT00984542Trial NCT00984490Trial NCT00983268Trial NCT00957736Trial NCT00949052Trial NCT00930930Trial NCT00900406Trial NCT00900003Trial NCT00899769Trial NCT00899626Trial NCT00899457Trial NCT00899301Trial NCT00899028Trial NCT00898742Trial NCT00898638Trial NCT00898430Trial NCT00898313Trial NCT00897988Trial NCT00897832Trial NCT00897793Trial NCT00897650Trial NCT00897468Trial NCT00897403Trial NCT00897117Trial NCT00896948Trial NCT00896675Trial NCT00892801Trial NCT00875238Trial NCT00840814Trial NCT00837876Trial NCT00835679Trial NCT00801346Trial NCT00765245Trial NCT00755040Trial NCT00675636Trial NCT00670644Trial NCT00670605Trial NCT00670046Trial NCT00666211Trial NCT00656604Trial NCT00653250Trial NCT00651976Trial NCT00651716Trial NCT00647218Trial NCT00626873Trial NCT00625417Trial NCT00625066Trial NCT00616590Trial NCT00601991Trial NCT00573404Trial NCT00550537Trial NCT00544648Trial NCT00533884

Abstract

PROJECT 002 ? HOST-TUMOR RESEARCH PROGRAM PROJECT SUMMARY/ABSTRACT The Host-Tumor Interactions Research Program (HT) consists of basic, translational and clinical scientists focused on discovering the interactions between tumor cells and their host, and developing strategies to interrupt those interactions in order to target and control tumor progression and metastasis. The central theme of HT is that tumor growth, invasion and metastasis depend not only on the tumor cell alone, but also on the complex interactions between the tumor cells and the host. In light of these realizations, the long-term scientific goal of HT is to develop a detailed and mechanistic understanding of not just the tumor cell and tumor mutations, but also all the components of the host microenvironment that influence cancer and the response to cancer therapy. These interactions are best studied by integrating knowledge and paradigms from many disciplines, including those not typically associated with cancer biology and oncology. In particular, in this renewal HT has taken advantage of the strength of its membership to explicitly incorporate individuals with imaging and modeling expertise to rigorously investigate the scientific goals of HT, which are to: ? Identify and validate molecular targets involved in communication between the tumor and host that contribute to tumor progression using sequencing and antibodies, probes and small molecules, imaging and computational modeling ? Develop in vitro and in vivo systems to test therapeutics and determine their mechanism of action ? Develop new methodologies capable of discovering and validating novel therapeutic targets ? Establish dynamic, multi-disciplinary collaborations that will accelerate these discoveries With these larger goals in mind, the strong expertise of the program is focused on cell-cell and cell-matrix interactions, angiogenesis and vasculogenesis, inflammation and tumor imaging and modeling. There are 39 program members from 15 departments and four schools with $7.6M in NCI funding and $6.4M in other peer-reviewed cancer-related funding. Out of 579 publications, 16% are intra-programmatic and 38% are inter-programmatic. Members also have 150 collaborative publications with investigators at other institutions.

View original record on NIH RePORTER →